Everest Medicines Sees Differentiated Strategy Leading To Trodelvy Success
China Situation Key
Executive Summary
Focused on the Chinese Market, the Shanghai-based bioventure is pushing ahead with a differentiated clinical development strategy for its top in-licensed asset Trodelvy, as an uphill fight looms over the antibody-drug conjugate therapy outside of China, the company’s president says in an interview.
You may also be interested in...
New Modalities Help Chinese Biotechs Win Investors’ Attention
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.
Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants
With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.
China Tweaks On-Site Inspection Priorities As Registration Filings Soar
China’s Center for Drug Evaluation has introduced a risk-based process to initiate on-site inspections related to drug registrations. It is hoped the novel system will suit the current capacity of auditor teams against a backdrop of an ongoing spike in product approval applications in the country since 2019.